- Home
- KYTX
as 04-18-2025 1:38pm EST
Stocks
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 125.2M | IPO Year: | 2024 |
| Target Price: | $18.80 | AVG Volume (30 days): | 298.8K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.79 - $22.44 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest KYVERNA THERAPEUTICS INC News
KYTX Breaking Stock News: Dive into KYTX Ticker-Specific Updates for Smart Investing
PR Newswire
22 days ago
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PR Newswire
2 months ago
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Simply Wall St.
2 months ago
3 US Penny Stocks With Market Caps Under $200M
Zacks
2 months ago
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
MT Newswires
3 months ago
Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer
PR Newswire
3 months ago
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
Simply Wall St.
3 months ago
Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation
PR Newswire
3 months ago
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Compare KYTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYTX KYVERNA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.